July 10, 2008
 

UPDATE 1-Pfizer argues against epilepsy drug warning - Reuters


UPDATE 1-Pfizer argues against epilepsy drug warning - Reuters
BELTSVILLE, Md., July 10 (Reuters) - Pfizer Inc (PFE.N: Quote , Profile , Research , Stock Buzz ) said its epilepsy drugs do not increase the risk of suicidal behavior and should be exempt from tougher warnings being sought for similar medications
Source: www.reuters.com

No China Trips by U.S. Food Inspectors - CNS News
(CNSNews.com) - U.S. Food and Drug Administration inspectors made 13 visits to Fiji in 2007 for food inspections and no visits at all to China, according to a study released to Congress recently by the Government Accountability Office (GAO). Fiji
Source: www.cnsnews.com

FDA Holds Hearings on Epilepsy Drug Suicide Risk - Wired
The potential suicide risk posed by eleven popular epilepsy drugs is the subject of a hearing held today by the U.S. Food and Drug Administration. An FDA analysis of 199 studies showed that .43 percent of people taking the drugs committed suicide or
Source: blog.wired.com

Pfizer denies suicide risks with epilepsy drugs - Forbes
Pfizer Inc. told government officials Thursday its drug Lyrica should not receive stern warnings about suicide risks that regulators are advocating for all epilepsy drugs. The world's largest drug maker defended the safety of its blockbuster
Source: www.forbes.com

FDA issues warning on Cipro, similar antibiotics - Washington Post
WASHINGTON -- Federal drug safety officials have imposed the government's most urgent warning on Cipro and similar antibiotics, citing risks that they can cause tendon ruptures, a serious injury that leaves some patients incapacitated. The Food and
Source: www.washingtonpost.com

Pfizer argues against epilepsy drug warning - Reuters
BELTSVILLE, Maryland (Reuters) - Pfizer Inc said its epilepsy drugs do not increase the risk of suicidal behavior and should be exempt from tougher warnings being sought for similar medications, despite concerns from U.S. health regulators. The
Source: www.reuters.com

Subscribe to Posts [Atom]